All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Visual abstract | Phase II trial of tamibarotene combination therapy in patients with newly diagnosed AML
Bookmark this article
The AML Hub is delighted to present a visual abstract summarizing key preliminary data from a phase II trial (NCT02807558) investigating the safety and efficacy of tamibarotene combination therapy in newly diagnosed adult patients with acute myeloid leukemia who are unfit for intensive chemotherapy. Tamibarotene is an oral, selective retinoic acid receptor alpha (RARα) agonist that received orphan drug designation from the U.S. Food and Drug Administration (FDA) in 2017 and has been previously discussed on by the AML Hub. This study compared response rates and survival outcomes in patients who were RARA-positive to patients who were RARA-negative.
Your opinion matters
15 votes - 80 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox